⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595638 | 0.81 | — | — | |
| SCHEMBL6563296 | 0.78 | — | — | |
| SCHEMBL29957195 | 0.77 | MAOB (0.41) | — | |
| SCHEMBL29957386 | 0.77 | MVD (0.40) | — | |
| SCHEMBL10733820 | 0.77 | TDP1 (0.52) | — | |
| SCHEMBL29952584 | 0.76 | — | — | |
| SCHEMBL22061 | 0.76 | TDP1 (0.47) | — | |
| SCHEMBL29024971 | 0.74 | TDP1 (0.33) | — | |
| SCHEMBL29956065 | 0.74 | PYCR1 (0.36) | — | |
| SCHEMBL8751680 | 0.74 | PYCR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812381-A | Method for synthesizing alpha-methyl-D-propargylglycine | 吉尔多肽生物制药(大连市)有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-11-14 | — | — | US | disclosed |
| CN-118812381-A | Method for synthesizing alpha-methyl-D-propargylglycine | 吉尔多肽生物制药(大连市)有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308699-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| WO-2010034029-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009099677-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-0792146-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997002028-A1 | INACTIVATION OF PATHOGENS USING HYDROXYMETHYLAMINES | HEMASURE, INC. (US) | 1997-01-23 | — | — | WO | disclosed |